tremelimumab,durvalumab,ipilimumab,nivolumab
bms,astrazeneca
[]
but at least in msi-h or dmmr patients, cr rates were excellent in the #neonipiga and #infinity trial. if it is supported by phase 3 studies, it will be the new standard. #gi23 
Hacettepe University, Department of Medical Oncology // Breast Cancer // Lung Cancer // Malign Melanoma